A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain (TRIUMPH-7)

May 19, 2026 updated by: Eli Lilly and Company

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly in Participants Who Have Obesity or Overweight and Chronic Low Back Pain

The main purpose of this study is to evaluate the efficacy and safety of retatrutide in relieving chronic low back pain in participants who have obesity or overweight. Participation in the study will last about 80 weeks.

Study Overview

Status

Recruiting

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

586

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
  • Phone Number: 1-317-615-4559
  • Email: LillyTrials@Lilly.com

Study Contact Backup

Study Locations

      • Buenos Aires, Argentina, C1426ABP
        • Recruiting
        • Fundación Respirar
        • Principal Investigator:
          • Marina Uhrig
        • Contact:
          • Phone Number: 5411 7078 1548
      • Buenos Aires, Argentina, C1061AAS
        • Recruiting
        • CIPREC
        • Contact:
          • Phone Number: 5491128690843
        • Principal Investigator:
          • Fernando Guerlloy
      • Buenos Aires, Argentina, C1056ABH
        • Recruiting
        • Investigaciones Medicas IMOBA SRL
        • Contact:
          • Phone Number: 05401162076305
        • Principal Investigator:
          • Aaron Kruler
      • Buenos Aires, Argentina, C1120AAC
        • Recruiting
        • Centro Médico Viamonte
        • Principal Investigator:
          • Diego Aizenberg
        • Contact:
          • Phone Number: 54 1149635650
      • Buenos Aires, Argentina, C1425AGC
        • Recruiting
        • Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada
        • Contact:
          • Phone Number: 541148019001
        • Principal Investigator:
          • Maria Coronel
      • Granadero Baigorria, Argentina, 2152
        • Recruiting
        • Centro de Investigaciones Clínicas Baigorria
        • Contact:
          • Phone Number: 543415593898
        • Principal Investigator:
          • Juan Escalante
      • Rosario, Argentina, 2000
        • Recruiting
        • Instituto Médico Catamarca IMEC
        • Contact:
          • Phone Number: 3416176661
        • Principal Investigator:
          • Natacha Maldonado
      • Rosario, Argentina, 2000
        • Recruiting
        • Centro Rosarino de Investigaciones Clinicas (CRICs)
        • Contact:
          • Phone Number: 03416744474
        • Principal Investigator:
          • Juan Loureyro
      • Santa Fe, Argentina, 3000
        • Recruiting
        • Centro de Diagnóstico y Rehabilitación (CEDIR)
        • Contact:
          • Phone Number: 5493424087292
        • Principal Investigator:
          • Antonio Saleme
      • Brampton, Canada, L6T 0G1
        • Recruiting
        • Aggarwal and Associates Limited
        • Contact:
          • Phone Number: 9054589033
        • Principal Investigator:
          • Naresh Aggarwal
      • Hamilton, Canada, L8J 0B6
        • Recruiting
        • Winterberry Research Inc.
        • Principal Investigator:
          • Steven Zizzo
        • Contact:
          • Phone Number: 365-366-6267
      • Sarnia, Canada, N7T 4X3
        • Recruiting
        • Bluewater Clinical Research Group Inc.
        • Principal Investigator:
          • John O'Mahony
        • Contact:
          • Phone Number: 1 (519) 344-6612
      • Sydney, Canada, B1M 0A1
        • Recruiting
        • Care Access - Cape Breton
        • Principal Investigator:
          • Tony Valente
      • Toronto, Canada, M9V 4B4
        • Recruiting
        • Dr. Anil K. Gupta Medicine Professional Corporation
        • Contact:
          • Phone Number: 6473442020
        • Principal Investigator:
          • Anil Gupta
      • Bialystok, Poland, 15-756
        • Completed
        • Podlaskie Centrum Psychogeriatrii
    • Arizona
      • Chandler, Arizona, United States, 85286
        • Recruiting
        • MD First Research - Chandler
        • Principal Investigator:
          • Hemant Pandey
        • Contact:
          • Phone Number: 480-508-1038
      • Tucson, Arizona, United States, 85712
        • Recruiting
        • Tucson Orthopaedic Institute - North Wyatt Drive
        • Principal Investigator:
          • Nebojsa Skrepnik
        • Contact:
          • Phone Number: 520-404-0276
    • California
      • Fountain Valley, California, United States, 92708
        • Recruiting
        • ARK Clinical Research - Fountain Valley
        • Principal Investigator:
          • Justin Yanuck
        • Contact:
          • Phone Number: 714-988-2021
      • Fullerton, California, United States, 92835
        • Recruiting
        • St Joseph Heritage Healthcare
        • Principal Investigator:
          • Shirley Pang
        • Contact:
          • Phone Number: 714-626-8610
      • Los Angeles, California, United States, 90048
        • Recruiting
        • Clinical Research Institute
        • Principal Investigator:
          • David Kudrow
        • Contact:
          • Phone Number: 323-879-9999
      • San Diego, California, United States, 92123
        • Recruiting
        • Artemis Institute for Clinical Research
        • Contact:
          • Phone Number: 858-278-3647
        • Principal Investigator:
          • Stacey Layle
    • Colorado
      • Boulder, Colorado, United States, 80301
        • Recruiting
        • Alpine Clinical Research Center
        • Contact:
          • Phone Number: 303-443-7229
        • Principal Investigator:
          • Paul Brownstone, MD
    • Florida
      • Daytona Beach, Florida, United States, 32114
        • Recruiting
        • K2 Medical Research - Daytona Beach
        • Principal Investigator:
          • Joshua Eisenhut
      • Miami, Florida, United States, 33135
        • Recruiting
        • Flourish Research - Miami, LLC
        • Principal Investigator:
          • Mark Kutner
        • Contact:
          • Phone Number: 305-631-6704
      • St. Petersburg, Florida, United States, 33704
        • Recruiting
        • IMA Clinical Research St. Petersburg
        • Contact:
          • Phone Number: 727-521-9137
        • Principal Investigator:
          • Howard Chipman
      • Tampa, Florida, United States, 33625
        • Recruiting
        • Care Access - Tampa
        • Principal Investigator:
          • Shital Mehta
        • Contact:
          • Phone Number: 813-771-5980
      • The Villages, Florida, United States, 32162
        • Recruiting
        • Charter Research - Lady Lake
        • Principal Investigator:
          • Stephen Miller
      • Winter Park, Florida, United States, 32789
        • Recruiting
        • Conquest Research
        • Principal Investigator:
          • Anand Patel
        • Contact:
          • Phone Number: 407-916-0060
    • Kansas
      • Topeka, Kansas, United States, 66606
        • Recruiting
        • Cotton O'Neil Clinical Research Center
        • Contact:
          • Phone Number: 785-354-9591
        • Principal Investigator:
          • Katherine Willingham
    • Louisiana
      • Lake Charles, Louisiana, United States, 70601
        • Recruiting
        • Care Access - Lake Charles (Bayou Pines)
        • Contact:
          • Phone Number: 337-602-6642
        • Principal Investigator:
          • William Nabours
    • Massachusetts
      • Waltham, Massachusetts, United States, 02451
        • Recruiting
        • MedVadis Research Corporation
        • Contact:
          • Phone Number: 617-744-1310
        • Principal Investigator:
          • David DiBenedetto
    • Michigan
      • Bay City, Michigan, United States, 48706
        • Recruiting
        • Great Lakes Research Group, Inc.
        • Contact:
          • Phone Number: 989-895-9100
        • Principal Investigator:
          • Jeffrey Potts
    • Missouri
      • Springfield, Missouri, United States, 65807
        • Recruiting
        • Clinvest Headlands Llc
        • Contact:
          • Phone Number: 417-883-7889
        • Principal Investigator:
          • Ralph Duda
    • North Carolina
      • Winston-Salem, North Carolina, United States, 27103
        • Recruiting
        • Center for Clinical Research
        • Principal Investigator:
          • Leonardo Kapural
    • Pennsylvania
      • Duncansville, Pennsylvania, United States, 16635
        • Recruiting
        • Altoona Center for Clinical Research
        • Principal Investigator:
          • Alan Kivitz
        • Contact:
          • Phone Number: 814-693-0300
    • Tennessee
      • Knoxville, Tennessee, United States, 37909
        • Recruiting
        • New Phase Research and Development
        • Principal Investigator:
          • Natalie Clarke
    • Texas
      • Austin, Texas, United States, 78731
        • Recruiting
        • FutureSearch Trials of Neurology
        • Contact:
          • Phone Number: 512-380-9925
        • Principal Investigator:
          • Gregory Tempest
      • Dallas, Texas, United States, 75208
        • Recruiting
        • Mercy Family Clinic
        • Contact:
          • Phone Number: 281-944-3610
        • Principal Investigator:
          • Ebere Israel Azubuike, MD
      • Houston, Texas, United States, 77079
        • Recruiting
        • Houston Research Institute
        • Principal Investigator:
          • David Huang
        • Contact:
          • Phone Number: 281-809-3234
    • Virginia
      • Danville, Virginia, United States, 24541
        • Recruiting
        • Sovah Clinical Research-River District
        • Principal Investigator:
          • James Dailey

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Have a history of axial-predominant low back pain
  • Have pain that is restricted to the low back or with a referral pattern limited to the proximal legs
  • Have a body mass index (BMI) ≥27 kilograms per square meter (kg/m2) at screening
  • Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight

Exclusion Criteria:

  • Have a non-axial origin low back pain
  • Have had botulinum or steroid injections to the spine within 1 year of screening
  • Have had trigger point injection to the spine within 6 months of screening
  • Have a self-reported change in body weight >5 kilograms (kg) (11 pounds) within 90 days prior to screening
  • Have been taking drugs to promote body weight reduction, including over-the-counter medications, within 90 days prior to screening
  • Have a prior or planned surgical treatment for obesity
  • Have Type 1 Diabetes, Type 2 Diabetes, or any other type of diabetes

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Placebo
Participants will receive Placebo SC
Administered SC
Experimental: Retatrutide
Participants will receive Retatrutide subcutaneously (SC)
Administered SC
Other Names:
  • LY3437943

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Change from Baseline in Pain Intensity Per Numeric Rating Scale
Time Frame: Baseline, up to 72 weeks
Baseline, up to 72 weeks
Percent Change from Baseline in Body Weight
Time Frame: Baseline, up to 72 weeks
Baseline, up to 72 weeks

Secondary Outcome Measures

Outcome Measure
Time Frame
Number of Participants with Reduction in Pain Intensity Per Numeric Rating Scale
Time Frame: Baseline, up to 72 weeks
Baseline, up to 72 weeks
Number of Participants with Reduction in Body Weight
Time Frame: Baseline, up to 72 weeks
Baseline, up to 72 weeks
Change in Physical Function as Measured by Patient-Reported Outcomes Measurement Information Systems (PROMIS)
Time Frame: Baseline, up to 72 weeks
Baseline, up to 72 weeks
Change in Pain Interference as Measured by PROMIS
Time Frame: Baseline, up to 72 weeks
Baseline, up to 72 weeks
Change in Sleep as Measured by PROMIS
Time Frame: Baseline, up to 72 weeks
Baseline, up to 72 weeks
Change in Patient Reported Health Outcomes as Measured by Medical Outcomes Study 36-item Short Form Health Survey version 2 (SF-36v2)
Time Frame: Baseline, up to 72 weeks
Baseline, up to 72 weeks
Change in Waist Circumference
Time Frame: Baseline, up to 72 weeks
Baseline, up to 72 weeks
Change in Biomarkers of Inflammation as Measured by Blood Test
Time Frame: Baseline, up to 72 weeks
Baseline, up to 72 weeks
Change in Blood Pressure
Time Frame: Baseline, up to 72 weeks
Baseline, up to 72 weeks
Change in Glycemic Control
Time Frame: Baseline, up to 72 weeks
Baseline, up to 72 weeks
Percent Change in Total Cholesterol
Time Frame: Baseline, up to 72 weeks
Baseline, up to 72 weeks
Percent Change in Urine Albumin-to-Creatinine Ratio (UACR)
Time Frame: Baseline, up to 72 weeks
Baseline, up to 72 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 29, 2025

Primary Completion (Estimated)

September 1, 2027

Study Completion (Estimated)

September 1, 2027

Study Registration Dates

First Submitted

May 28, 2025

First Submitted That Met QC Criteria

June 16, 2025

First Posted (Actual)

June 24, 2025

Study Record Updates

Last Update Posted (Actual)

May 20, 2026

Last Update Submitted That Met QC Criteria

May 19, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 27278
  • 2024-517431-43-00 (Ctis)
  • J1I-MC-GZQD (Other Identifier: Eli Lilly and Company)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

IPD Sharing Time Frame

Data are available 6 months after the primary publication or approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

IPD Sharing Access Criteria

A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Obesity

Clinical Trials on Placebo

Subscribe